Vascular Biogenics Ltd (VBLT)

[Valueinvestor12]

This is released today 11-10-17 from the Japaneses company nanocarrier quarterly report:

"on November 3, 2017, we
concluded a licensing agreement with Vascular Biogenics Ltd. (based in Israel, listed as VBL Therapeutics (VBLT) on US;
Nasdaq) for development and commercialization in Japan of its gene therapy-based drug VB-111 that induces apoptosis
selectively in tumor vasculature. VB-111 is a first-in-class gene therapy-based drug that has already completed the registration of
patients in Phase III trials ahead of other clinical trials, mainly in the US, for the indication of recurrent glioblastoma (rGBM),
the type of brain cancer that has been most difficult to treat. VB-111 is expected to receive early approval. In addition, mainly in
the US, Phase II trials are underway for the indications of platinum-resistant ovarian cancer and thyroid cancer. Under the
agreement+,

top on page 6 in this link http://xml.irpocket.com/C4571/20171110TENMYH.pdf